Inhibikase Therapeutics (IKT) Cash & Current Investments (2020 - 2025)
Historic Cash & Current Investments for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to $77.3 million.
- Inhibikase Therapeutics' Cash & Current Investments rose 228380.57% to $77.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.3 million, marking a year-over-year increase of 228380.57%. This contributed to the annual value of $97.5 million for FY2024, which is 63606.36% up from last year.
- As of Q3 2025, Inhibikase Therapeutics' Cash & Current Investments stood at $77.3 million, which was up 228380.57% from $87.7 million recorded in Q2 2025.
- In the past 5 years, Inhibikase Therapeutics' Cash & Current Investments ranged from a high of $97.5 million in Q4 2024 and a low of $3.2 million during Q3 2024
- In the last 5 years, Inhibikase Therapeutics' Cash & Current Investments had a median value of $26.5 million in 2022 and averaged $37.6 million.
- Its Cash & Current Investments has fluctuated over the past 5 years, first surged by 60152563.9% in 2021, then crashed by 8072.88% in 2024.
- Quarter analysis of 5 years shows Inhibikase Therapeutics' Cash & Current Investments stood at $40.8 million in 2021, then tumbled by 43.44% to $23.1 million in 2022, then crashed by 42.51% to $13.3 million in 2023, then skyrocketed by 636.06% to $97.5 million in 2024, then decreased by 20.73% to $77.3 million in 2025.
- Its last three reported values are $77.3 million in Q3 2025, $87.7 million for Q2 2025, and $93.2 million during Q1 2025.